Roche Holding AG is the owner of F. Hoffmann-La Roche Ltd., a provider of in-vitro diagnostics and drugs for cancer and transplantation. It specializes in medicines for oncology, virology, inflammation, metabolism, CNS, clinical chemistry, immunology, urinalysis, blood screening, genetics, infectious diseases, and microbiology. F. Hoffmann-La Roche Ltd. serves  hospitals, research labs, private medical labs, practicing physicians, and patients.

Its products include cancer treatments, such as Avastin, Herceptin, and MabThera that are also effective in the treatment of rheumatoid arthritis, anemia, and osteoporosis. F. Hoffmann-La Roche Ltd., also conducts research and development as well as production related to molecular diagnostic reagents, test systems, and test kits. In addition, it provides automated instruments, software, consumables, and IT solutions used in in-vitro diagnostics and research.

F. Hoffmann-La Roche Ltd was established in 1896 and is based in Basel, Switzerland.